ClinicaltodayNew
Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation - finance.biggo.com
Moderna and Merck reported that their personalized mRNA cancer vaccine mRNA-4157 met its primary endpoint in the Phase 3 INTerpath-001 trial, which enrolled 1,137 high-risk melanoma patients after complete surgical resection. The vaccine combined with Keytruda produced statistically significant improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda monotherapy. The result added more than $50 billion in combined market value to the two companies, with Moderna’s stock rising 177% and adding about $44 billion, and is pushing oncology sequencing and diagnostics into the capital-markets spotlight. It also heightens speculation around Tempus AI’s Personalis bid and rivalry in the sequencing sector.